Pinnacle Financial Partners Inc Grows Stock Position in CME Group Inc. $CME

Pinnacle Financial Partners Inc raised its holdings in shares of CME Group Inc. (NASDAQ:CME) by 2.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,111 shares of the financial services provider’s stock after acquiring an additional 2,108 shares during the quarter. Pinnacle Financial Partners Inc’s holdings in CME Group were worth $28,940,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of CME. Norges Bank acquired a new position in shares of CME Group during the 2nd quarter worth approximately $1,571,447,000. Viking Global Investors LP purchased a new position in CME Group during the second quarter worth $164,648,000. Vanguard Group Inc. raised its holdings in shares of CME Group by 1.5% in the second quarter. Vanguard Group Inc. now owns 35,176,376 shares of the financial services provider’s stock worth $9,695,313,000 after acquiring an additional 532,549 shares during the last quarter. Magellan Asset Management Ltd lifted its position in shares of CME Group by 131,625.5% in the second quarter. Magellan Asset Management Ltd now owns 486,067 shares of the financial services provider’s stock valued at $133,970,000 after acquiring an additional 485,698 shares in the last quarter. Finally, HRT Financial LP acquired a new position in CME Group in the 2nd quarter valued at about $127,103,000. Hedge funds and other institutional investors own 87.75% of the company’s stock.

CME Group News Summary

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: CME plans to add Cardano (ADA), Chainlink (LINK) and Stellar (XLM) futures — standard and micro contracts — boosting crypto product breadth and capital‑efficient tools for clients; listing targeted for Feb. 9 pending review, which could lift futures trading volumes and fee revenue. CME Group Expands Crypto Futures With Cardano, Chainlink, and Stellar
• Positive Sentiment: TD Cowen upgraded CME to “Buy”, signaling constructive analyst sentiment that supports upside and likely helped investor confidence. TD Cowen Upgrades CME Group (NASDAQ:CME) to “Buy”
• Positive Sentiment: CME is introducing a new, smaller silver futures contract to capture surging retail interest in silver — a product move that can broaden participation and boost notional volumes in metals. Silver Gets a Major Upgrade: CME to Launch New Futures as Retail Demand Hits Record Levels
• Neutral Sentiment: Jefferies trimmed its price target slightly (from $304 to $302) but kept a “Buy” rating — modestly lowering upside but still supportive. Jefferies Adjusts Price Target on CME Group
• Neutral Sentiment: Morgan Stanley cut its price target by $1 to $319 while retaining an “Overweight” rating — a slight tweak that keeps a bullish stance but marginally lowers modeled upside. Morgan Stanley Lowers CME Price Target
• Neutral Sentiment: Analyst previews and coverage notes (e.g., “Here’s What to Expect From CME Group’s Next Earnings Report”) keep focus on volumes/fee trends and macro volatility — useful context but not immediate catalysts. Here’s What to Expect From CME Group’s Next Earnings Report
• Negative Sentiment: Goldman Sachs nudged its target slightly lower (from $265 to $264) and maintains a “Sell” rating — a visible negative outlier that can weigh on sentiment among more cautious investors. Goldman Sachs Adjusts CME Group Price Target

Insider Activity

In related news, Director William R. Shepard acquired 251 shares of the firm’s stock in a transaction on Tuesday, December 30th. The stock was bought at an average cost of $278.37 per share, with a total value of $69,870.87. Following the acquisition, the director directly owned 258,710 shares in the company, valued at approximately $72,017,102.70. The trade was a 0.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Harold Eugene Jr. Ford sold 1,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $263.53, for a total transaction of $263,530.00. Following the completion of the sale, the director directly owned 1,091 shares of the company’s stock, valued at $287,511.23. The trade was a 47.82% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

CME has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft lifted their price target on CME Group from $310.00 to $318.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. TD Cowen upgraded shares of CME Group from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $290.00 to $305.00 in a research note on Wednesday. The Goldman Sachs Group cut their target price on shares of CME Group from $265.00 to $264.00 and set a “sell” rating on the stock in a research note on Wednesday. UBS Group reaffirmed a “neutral” rating on shares of CME Group in a research report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. raised their price objective on CME Group from $252.00 to $256.00 and gave the company an “underweight” rating in a research report on Tuesday, October 14th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, CME Group has an average rating of “Hold” and an average target price of $291.82.

CME Group Stock Performance

NASDAQ:CME opened at $279.44 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. The firm has a 50-day moving average of $274.20 and a two-hundred day moving average of $271.84. The stock has a market cap of $100.77 billion, a P/E ratio of 27.08, a PEG ratio of 3.08 and a beta of 0.27. CME Group Inc. has a 1-year low of $230.19 and a 1-year high of $290.79.

CME Group (NASDAQ:CME) last announced its earnings results on Wednesday, October 22nd. The financial services provider reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.63 by $0.05. The business had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.56 billion. CME Group had a return on equity of 14.61% and a net margin of 58.84%.The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.68 earnings per share. On average, research analysts expect that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Friday, December 12th were given a $1.25 dividend. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend was Friday, December 12th. CME Group’s dividend payout ratio is presently 48.45%.

CME Group Profile

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.